Mifepristone is an active ingredient that is used in some medicines.

Mifepristone is also known as RU486.

The active ingredient is the chemical in a medicine that makes it work. Medicines can have more than one active ingredient and be available under different brand names. Medicines include both active ingredients and inactive ingredients.

This page about mifepristone automatically lists related information collected from other pages of our website.

The list below also includes links to brands of medicines that contain mifepristone, including their consumer medicine information (CMI) leaflets.

Consumers: If you have any questions about medicines, you can speak to one of our pharmacists at NPS Medicines Line by calling 1300 633 424. You can ring Monday to Friday, 9 am to 5 pm, Australian Eastern Standard Time (excluding NSW public holidays). For non-medicine products, further information may also be available from the manufacturer.

Related information - mifepristone


02 Nov 2016 Mifepristone Linepharma Tablets is a brand of medicine. Find out about side effects, who can and who shouldn’t use Mifepristone Linepharma Tablets by reading the latest Australian consumer medicine information. See our tips on how to use medicines wisely and safely.
(Health professional publication)
01 Feb 2015 From 1 February 2015 a mifepristone–misoprostol composite pack (MS-2 Step) is PBS listed for medical termination of an intrauterine pregnancy up to 63 days’ gestation, up from the previous 49 days’ gestation.
(Consumer publication)
01 Feb 2015 Mifepristone (also known as RU486 or the ‘abortion pill’) and misoprostol are two medicines that can be used as an alternative to surgical termination (abortion) of a pregnancy. They are taken in sequence up to 49 days after your last period.
(Media release)
23 Sep 2013 NPS MedicineWise has published information for women who are considering medical termination of early pregnancy using mifepristone (RU486) and misoprostol
(Media release)
01 Aug 2013 The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme (PBS) including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).
For health professionals (Health professional publication)
01 Aug 2013 Medical termination of a pregnancy of up to 49 days’ gestation using mifepristone followed by misoprostol is a well-established regimen that is safe and effective. It can be offered to a woman as an alternative to surgical termination of pregnancy when it is suitable for her.
(Media release)
26 Apr 2013 NPS MedicineWise supports the scientific and evidence-based recommendation made today that medical abortion drug, mifepristone (RU486), should be subsidised under the Pharmaceutical Benefits Scheme (PBS).
For health professionals (Health professional publication)
17 Nov 2012 Mifepristone (RU 486) and misoprostol (Cytotec) are now available to a wider group of Australian women for medical termination of pregnancy, following their approval for this indication by the Therapeutic Goods Administration in August. Suitably trained medical practitioners can now prescribe these drugs as an alternative to surgery for women in the early weeks of pregnancy.

Medicine brands that contain mifepristone